Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 10
Submit an article Journal homepage
315
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent Advances in the Discovery of Small Molecule Mtor Inhibitors

Abhijit Roychowdhury1 Departments of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon, Off Western Express Highway, Goregaon (E) Mumbai, IndiaView further author information
,
Rajiv Sharma1 Departments of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon, Off Western Express Highway, Goregaon (E) Mumbai, IndiaView further author information
&
Sanjay Kumar1 Departments of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon, Off Western Express Highway, Goregaon (E) Mumbai, IndiaCorrespondence[email protected]
View further author information
Pages 1577-1589 | Published online: 13 Oct 2010

Bibliography

  • Hay N . The Akt-mTOR tango and its relevance to cancer.Cancer Cell8, 179–183 (2005).
  • Faivre S , KroemerG, RaymondE. Current development of mTOR inhibitors as anticancer agents.Nat. Rev. Drug Discov.5, 671–688 (2006).
  • Baldo P , CeccoS, GiacominEet al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets 8, 647–665 (2008).
  • Fingar DC , BlenisJ. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.Oncogene23, 3151–3171(2004).
  • Guertin DA , SabatiniDM. Defining the role of mTOR in cancer.Cancer Cell12, 9–22 (2007).
  • Guertin DA , SabatiniDM. An expanding role for mTOR in cancer.Trends Mol. Med.11, 353–361 (2005).
  • Martin DE , HallMN. The expanding TOR signaling network.Curr. Opin. Cell Biol.17, 158–166 (2005).
  • Harrington LS , FindlayGM, LambRF. Restraining PI3K: mTOR signalling goes back to the membrane.Trends Biochem. Sci.30, 35–42 (2005).
  • Dos Santos S , DelattreAI, De Longueville F et al. Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kB and PI3K/mTOR signaling pathways. Ann. N.Y. Acad. Sci.1096, 70–77 (2007).
  • Weinstein SL , FinnAJ, DaveSHet al. Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-β. J. Leukoc. Biol. 67, 405–414 (2000).
  • Kristof AS , Marks-KonczalikJ, BillingsEet al. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of rapamycin. J. Biol. Chem. 278, 33637–33644 (2003).
  • Farkas S , HornungM, SattlerCet al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int. J. Colorectal Dis. 21, 747–753 (2006).
  • Matsuda C , ItoT, SongJet al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin. Exp. Immunol. 148, 348–359 (2007).
  • Deore V , YewalkarN, BhatiaDet al. Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg. Med. Chem. Lett. 19, 2949–2952 (2009).
  • Cota D , ProulxK, SmithKAet al. Hypothalamic mTOR signaling regulates food intake. Science 312, 927–930 (2006).
  • Harrison DE , StrongR, SharpZDet al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
  • Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations.Nat. Rev. Cancer9, 550–562 (2009).
  • Liu P , ChengH, RobertsTMet al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627–644 (2009).
  • Brachmann S , FritschC, MairaSMet al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21, 194–198 (2009).
  • Guertin DA , Sabatini,DM. The pharmacology of mTOR inhibition: the quest for effective cancer therapies reveals insight into the regulation and function of the mammalian target of rapamycin.Science Signaling2(67), 24 (2009).
  • Laplante M , SabatiniDM. mTOR signaling at a glance.J. Cell Sci.122, 3589–3594 (2009).
  • Liu Q , ThoreenC, WangJet al. mTOR mediated anticancer drug discovery. Drug Discov. Today Therapeutic Strat. 6(2), 47–55 (2010).
  • Huang J , WuS, WuCLet al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 69, 6107–6114 (2009).
  • Raje N , KumarS, HideshimaTet al. Anderson Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188–4193 (2004).
  • Vignot S , FaivreS, AguirreDet al. mTOR-targeted therapy of cancer with rapamycin derivatives. Annal. Oncology 16, 525–537 (2005).
  • Hartford CM , RatainMJ. Rapamycin: something old, something new, sometimes borrowed and now renewed.Clin. Pharmacol. Ther.82, 381–388 (2007).
  • Sarbassov DD , AliSMet al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
  • Choi J , ChenJ, SchreiberSLet al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239–342 (1996).
  • Wullschleger S , LoewithR, HallMN. TOR signaling in growth and metabolism.Cell124, 471–484 (2006).
  • Kurmasheva RT , HuangS, HoughtonPJ. Predicted mechanisms of resistance to mTOR inhibitors.Br. J. Cancer95, 955–960 (2006).
  • Huang S , BjornstiMA, HoughtonPJ. Rapamycins: mechanism of action and cellular resistance.Cancer Biol. Ther.2, 222–232 (2003).
  • Chen Y , ZhengYet al. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22, 3937–3942 (2003).
  • Neuhaus P , KluppJ, LangrehrJM. mTOR inhibitors: an overview.Liv. Transplantation7, 473–484 (2001).
  • Sehgal SN , BakerH, VezinaC. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.J. Antibiot. (Tokyo)28, 727–732 (1975).
  • Martel RR , KliciusJ, GaletS. Inhibition of the immune response by rapamycin, a new antifungal antibiotic.Can. J. Physiol. Pharmacol.55, 48–51 (1977).
  • Cardenas ME , CruzMC, Del Poeta M et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev.12, 583–611 (1999).
  • Singh N , HeitmanJ. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients.Transplantation77, 795–800 (2004).
  • Dumont FJ , SuQ. Mechanism of action of the immunosuppressant rapamycin.Life Sci.58, 373–395 (1996).
  • Tamburini J , ChapuisN, BardetVet al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379–382 (2008).
  • Tamburini J , GreenAS, BardetVet al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114, 1618–1627 (2009).
  • Menear KA , GomezS, MalaguKet al. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett. 19, 5898–5901 (2009).
  • Richard DJ , VerheijenJC, YuKet al. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα. Bioorg. Med. Chem. Lett. 2010, 20, 2654–2657 (2010).
  • Malagu K , DugganH, MenearKet al. The discovery and optimization of pyrido[2,3-d] pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg. Med. Chem. Lett. 19, 5950–5953 (2009).
  • Garcia-Martinez JM , MoranJ, ClarkeRGet al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
  • Zask A , VerheijenJC, CurranKet al. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem. 52, 5013–5016 (2009).
  • Zask A , KaplanJ, VerheijenJCet al. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem. 52, 7942–7945 (2009).
  • Richard DJ , VerheijenJC, CurranKet al. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg. Med. Chem. Lett. 19, 6830–6835 (2009).
  • Curran KJ , VerheijenJC, KaplanJet al. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Bioorg. Med. Chem. Lett. 20, 1440–1444 (2010).
  • Verheijen JC , RichardDJ, CurranKet al. 2-arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability. Bioorg. Med. Chem. Lett. 20, 2648–2653 (2010).
  • Zask A , VerheijenJC, RichardDJet al. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 2644–2647 (2010).
  • Verheijen JC , YuK, Toral-BarzaLet al. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Bioorg. Med. Chem. Lett. 20, 375–379 (2010).
  • Dehnhardt CM , VenkatesanAM, SantosEDet al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem. 53(2), 798–810 (2010).
  • Venkatesan AM , DehnhardtCM, ChenZet al. Novel imidazolopyrimidines as dual PI3-kinase/mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 653–656 (2010).
  • Tsou HR , MacEwanG, BirnbergGet al. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran- 3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 2321–2325 (2010).
  • Kaplan J , VerheijenJC, BrooijmansNet al. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 640–643 (2010).
  • Knight SD , AdamsND, BurgessJLet al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapapmycin. ACS Med. Chem. Lett. 1(1), 39–43 (2010).
  • Raynaud FI , EcclesSA, PatelSet al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8(7), 1725–1738 (2009).
  • Ihle NT , PowisG. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.Mol. Cancer Ther.8(1), 1–9 (2009).
  • Marone R , CmiljanovicV, GieseBet al. Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim. Biophys. Acta. 1784, 159–185 (2008).
  • Maira SM , StaufferF, SchnellCet al. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc. Trans. 37, 265–272 (2009).
  • Maira SM , FuretP, StaufferF. Discovery of novel anticancer therapeutics targeting the PI3K/AKt/mTOR pathway.Future Med. Chem.1(1), 137–155 (2009).

Patents

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.